Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9209MR)

This product GTTS-WQ9209MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9209MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14753MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ9388MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ11229MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ12798MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ807MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ2336MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ3375MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AT-005
GTTS-WQ5456MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDA 1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW